Swan House and Vita Spring Pavilion

QuantuMDx Enters into Cooperation Agreement with Sansure Biotech

Retrieved on: 
Tuesday, September 6, 2022
Dai, Partnership, VP, COVID-19, Medtech, Research, IVDR, UPON, Shanghai Stock Exchange, STAR, Review, Swan House and Vita Spring Pavilion, Severe acute respiratory syndrome coronavirus 2, PCR, Financial adviser, Interview, Point, WG, CE, Marketing communications, Patient, Medical device

QuantuMDx Group Limited (QuantuMDx), today announces it has entered into a cooperation agreement with Sansure Biotech Inc. (Sansure), an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC and its assays, in China.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today announces it has entered into a cooperation agreement with Sansure Biotech Inc. (Sansure), an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC and its assays, in China.
  • Under the terms of the agreement, QuantuMDx and Sansure will enter a global R&D, manufacturing and commercial partnership aimed to bring a comprehensive array of innovative, high-performance molecular diagnostic assays to the Q-POC platform.
  • QuantuMDx will grant Sansure exclusive rights to Q-POC in China, for which QuantuMDx will receive licensing and royalty payments.
  • Jonathan OHalloran, Chief Executive, QuantuMDx, said: Sansure is an excellent partner for QuantuMDx in China as we look to increase our global presence.

QuantuMDx Enters into Cooperation Agreement with Sansure Biotech

Retrieved on: 
Tuesday, September 6, 2022
Dai, Partnership, VP, COVID-19, Medtech, Research, IVDR, UPON, Shanghai Stock Exchange, STAR, Review, Swan House and Vita Spring Pavilion, Severe acute respiratory syndrome coronavirus 2, PCR, Financial adviser, Interview, Point, WG, CE, Marketing communications, Patient, Medical device

QuantuMDx Group Limited (QuantuMDx), today announces it has entered into a cooperation agreement with Sansure Biotech Inc. (Sansure), an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC and its assays, in China.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today announces it has entered into a cooperation agreement with Sansure Biotech Inc. (Sansure), an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC and its assays, in China.
  • Under the terms of the agreement, QuantuMDx and Sansure will enter a global R&D, manufacturing and commercial partnership aimed to bring a comprehensive array of innovative, high-performance molecular diagnostic assays to the Q-POC platform.
  • QuantuMDx will grant Sansure exclusive rights to Q-POC in China, for which QuantuMDx will receive licensing and royalty payments.
  • Jonathan OHalloran, Chief Executive, QuantuMDx, said: Sansure is an excellent partner for QuantuMDx in China as we look to increase our global presence.

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Retrieved on: 
Monday, November 8, 2021
Dai, Pharmacy, Strategic Cooperation Agreement, Strategic management, PCR, Technology, STI, Shanghai Stock Exchange, HPV, Research, STAR, Hospital, Company, Financial adviser, Solution, Swan House and Vita Spring Pavilion, Pharmaceutical industry, Renewable energy, Medical device

QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.
  • Additionally, QuantuMDx and Sansure Biotech Inc. (Sansure) have entered discussions for a Cooperation Agreement.
  • Sansure is an in-vitro diagnostic solution provider founded in Changsha, Hunan province, China in 2008, with over 1,500 employees and a broad product portfolio.
  • Sansures founder and Chairman, Dr Li Zhong Dai, is a scientific advisor to Vita Spring.

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Retrieved on: 
Monday, November 8, 2021
Dai, Pharmacy, Strategic Cooperation Agreement, Strategic management, PCR, Technology, STI, Shanghai Stock Exchange, HPV, Research, STAR, Hospital, Company, Financial adviser, Solution, Swan House and Vita Spring Pavilion, Pharmaceutical industry, Renewable energy, Medical device

QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.
  • Additionally, QuantuMDx and Sansure Biotech Inc. (Sansure) have entered discussions for a Cooperation Agreement.
  • Sansure is an in-vitro diagnostic solution provider founded in Changsha, Hunan province, China in 2008, with over 1,500 employees and a broad product portfolio.
  • Sansures founder and Chairman, Dr Li Zhong Dai, is a scientific advisor to Vita Spring.